Cited by 644Metabolism, Diabetes, and CancerAutophagy in Disease and TherapyATP Synthase and ATPases Research

Low-dose metformin targets the lysosomal AMPK pathway through PEN2

Open access
Ma, Teng, Tian, Xiao, Zhang, Baoding, Li, Mengqi, Wang, Yu, Yang, Chunyan, Wu, Jianfeng, Wei, Xiaoyan +27 more·2022·Nature

Abstract

Metformin, the most prescribed antidiabetic medicine, has shown other benefits such as anti-ageing and anticancer effects 1–4 . For clinical doses of metformin, AMP-activated protein kinase (AMPK) has a major role in its mechanism of action 4,5 ; however, the direct molecular target of metformin remains unknown. Here we show that clinically relevant concentrations of metformin inhibit the lysosomal proton pump v-ATPase, which is a central node for AMPK activation following glucose starvation 6 . We synthesize a photoactive metformin probe and identify PEN2, a subunit of γ-secretase 7 , as a binding partner of metformin with a dissociation constant at micromolar levels. Metformin-bound PEN2 forms a complex with ATP6AP1, a subunit of the v-ATPase 8 , which leads to the inhibition of v-ATPase and the activation of AMPK without effects on cellular AMP levels. Knockout of PEN2 or re-introduction of a PEN2 mutant that does not bind ATP6AP1 blunts AMPK activation. In vivo, liver-specific knockout of Pen2 abolishes metformin-mediated reduction of hepatic fat content, whereas intestine-specific knockout of Pen2 impairs its glucose-lowering effects. Furthermore, knockdown of pen-2 in Caenorhabditis elegans abrogates metformin-induced extension of lifespan. Together, these findings reveal that metformin binds PEN2 and initiates a signalling route that intersects, through ATP6AP1, the lysosomal glucose-sensing pathway for AMPK activation. This ensures that metformin exerts its therapeutic benefits in patients without substantial adverse effects.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-022-04431-8

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The pro-inflammatory cytokine network is one potential anti-aging target, using anti-inflammation drugs such as metformin, aspirin, rapamycin, and ibuprofen.

    “Recent studies have demonstrated that the pro-inflammatory cytokine network is one potential anti-aging target, using anti-inflammation drugs such as metformin, aspirin, rapamycin, and ibuprofen.”

    From Inflammation and aging: signaling pathways and intervention therapies (2023) · cites this paper as [339]

    The Main section says metformin can extend lifespan and health span in nematodes and mice, and the Discussion reports lifespan extension through the PEN2–ATP6AP1–AMPK pathway. The paper does not identify the pro-inflammatory cytokine network as the target of that effect or support the claim about aspirin, rapamycin and ibuprofen as anti-aging drugs. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Metformin can reduce chronic inflammation and improve healthy mid-life aging by acting on targets such as IKK/NF-κB in patients with Type 2 diabetes, as well as GPX7/NRF2 and PEN2.

    “For example, metformin can reduce chronic inflammation and improve healthy mid-life aging by acting on possible targets such as IKK/NF-κB in patients with Type 2 diabetes,337 as well as GPX7/NRF2338 and a recently found target, PEN2.339”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ma, T., Tian, X., Zhang, B., Li, M., Wang, Y., Yang, C., Wu, J., Wei, X., Qu, Q., Yu, Y., Long, S., Feng, J.-W., Li, C., Zhang, C., Xie, C., Wu, Y., Xu, Z., Chen, J., Yu, Y., Huang, X., He, Y., Yao, L., Zhang, L., Zhu, M., Wang, W., Wang, Z.-C., Zhang, M., Bao, Y., Jia, W., Lin, S.-Y., Ye, Z., Piao, H.-L., Deng, X., Zhang, C.-S., & Lin, S.-C.
Affiliations
  • Xiamen University (CN)
  • Dalian Institute of Chemical Physics (CN)
  • Shanghai Jiao Tong University (CN)
Corresponding author
  • Zhang, Cixiong
  • Deng, Xianming
  • Zhang, Chen-Song
Venue
Nature
Published
2022-02-23
Volume
603
Issue
7899
Pages
159-165
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4213415596
Cited by
644
References
64
Citations by year
2026: 137 · 2025: 171 · 2024: 155 · 2023: 113 · 2022: 68
FWCI
41.67
Type
journal article
Language
en
Open access
Locations
  • Nature (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Epidemiology › Autophagy in Disease and Therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › ATP Synthase and ATPases Research
Keywords
metformin, AMPK activation, Pen-2, V-ATPase, ATP6AP1, AMPK-independent mechanism, glucose-lowering effect, lifespan extension, Caenorhabditis elegans, drug target identification
MeSH terms
Adenosine Triphosphatases, Animals, Diabetes Mellitus, Glucose, Humans, Hypoglycemic Agents, Lysosomes, Membrane Proteins, Metformin, Caenorhabditis elegans, Vacuolar Proton-Translocating ATPases, Amyloid Precursor Protein Secretases, AMP-Activated Protein Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review